WIF 1804
Alternative Names: WIF-1804Latest Information Update: 04 Mar 2021
At a glance
- Originator Whanin Pharmaceutical
- Class Antidepressants
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Research Depressive disorders
Most Recent Events
- 16 Feb 2021 WIF 1804 is available for licensing as of 16 Feb 2021. https://www.whanin.com/_commonBase/content.php?co_id=outlicense_kor#
- 16 Feb 2021 Early research in Depressive disorders in South Korea (unspecified route) before February 2021 (Whanin Pharmaceutical pipeline, February 2021)